U.S. FDA clears LensAR ophthalmic laser system for additional utility

Ophthalmic laser system maker LensAR (Orlando, FL) has received U.S. FDA clearance for the its LENSAR Laser System with Streamline IV, expanding the platform's capabilities to include the creation of the corneal pockets and flaps used in ophthalmic procedures for treating presbyopia.

Related: FDA clears open-architecture advancements for LensAR ophthalmology laser

The presbyopia procedure features of the LENSAR Laser System with Streamline IV include a new curved contact patient interface device that enables the creation of corneal pockets and flaps without compromising patient comfort.

The new presbyopia procedure capabilities will be rolling out to LensAR users in the U.S. in 2018. The company has applied for regulatory approval in the EU and anticipates availability of the new features there later in 2018, pending approval.

For more information, please visit www.lensar.com.